EA Pharma’s transformation into a gastroenterology specialty pharmaceutical company
First written in FY2016. 3 of 5 entries say "Restated". Latest entry: FY2017.
4 other companies' latest entry also says "Advanced".
- FY2017AdvancedAnnual report
「<Main Strategic Initiatives> 1. Strengthening the business structure (FIT) • Progress has been made in restructuring the pharmaceutical business through the establishment of EA Pharma Co., Ltd.」
The restructuring of the pharmaceutical business through the establishment of EA Pharma was positioned as a key achievement under the medium-term management plan. - FY2017-Q3RestatedAnnual report
「In the pharmaceutical business, the company aims to become Japan’s largest gastrointestinal specialty pharmaceutical company through the integration, by absorption-type company split, of Eisai Co.,Ltd.’s gastrointestinal disease business and 味の素製薬株式会社, through EA Pharma Co., Ltd., launched in April 2016. It will improve profitability through sales synergies and greater efficiency, including a review of overlapping functions, secure sufficient resources for new drug development and achieve sustained growth.」
The company continues to pursue a growth policy through EA Pharma’s sales synergies and greater efficiency following the integration, as well as securing resources for new drug development. The ownership interest is 40%, and EA Pharma is an equity-method associate. - FY2017-Q2RestatedAnnual report
「As a result, from the first quarter of the current fiscal year, the company’s ownership interest in EA Pharma Co., Ltd. became 40%, and the company changed from a consolidated subsidiary, specifically a specified subsidiary, to an equity-method associate.」
The company continues to pursue a growth policy based on EA Pharma’s sales synergies, greater efficiency and securing resources for new drug development following the integration. The company holds a 40% interest, and EA Pharma is an equity-method associate. - FY2017-Q1RestatedAnnual report
「As a result, from the first quarter of the current fiscal year, the company’s ownership interest in EA Pharma Co., Ltd. became 40%, and the company changed from a consolidated subsidiary, specifically a specified subsidiary, to an equity-method associate. The newly integrated company will improve profitability through sales synergies from the integration and greater efficiency, including a review of overlapping functions, secure sufficient resources for new drug development and achieve sustained growth.」
The company reconfirmed its policy of growth through EA Pharma’s transition to an equity-method associate following the integration, sales synergies, greater efficiency and securing resources for new drug development. - FY2016First statedAnnual report
「In the pharmaceutical business, the company aims to become Japan’s largest gastrointestinal specialty pharmaceutical company through the integration, by absorption-type company split, of Eisai Co.,Ltd.’s gastrointestinal disease business and 味の素製薬株式会社. Through EA Pharma Co., Ltd., launched in April 2016, it will improve profitability through sales synergies and greater efficiency, including a review of overlapping functions, secure sufficient resources for new drug development and achieve sustained growth.」
EA Pharma was launched through an absorption-type company split on 1 April 2016 and became an equity-method associate in which the company holds a 40% interest.